RPCEC00000092暂停3 期
Efficacy and safety of ior EPOCIM in reducing transfusion requirements in elective surgical patients with benign prostatic hyperplasia.
Center of Molecular Immunology(CIM)0 个研究点目标入组 306 人开始时间: 2009年10月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 发起方
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 19 years 至 none（—）
- 性别
- Male
入选标准
- •1.Patients who fulfill the diagnostic criteria.
- •2.Patients older than 18 years.
- •3.Patients give their informed consent to participate in writing.
排除标准
- •1.Uncontrolled hypertension.
- •2.Patients with known risk or a history of arterial or venous thromboembolic disease.
- •3.Severe cardiovascular disease: unstable angina, heart failure, aortic stenosis.
- •4.Severe vascular brain disease.
- •5.Known infectious diseases such as HIV/AIDS,Hepatitis B and C.
- •6.Patients with known hypersensitivity to products derived from cells above or hypersensitivity to human albumin.
- •7.Hematologic Diseases:Sicklemia,Myelodysplastic syndromes,Disorders of coagulation. 8.Surgical approach to patients with benign prostatic hyperplasia by transurethral.
研究者
相似试验
已完成
4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.Chronic Renal Insufficiency.RPCEC00000082Center of Molecular Immunology(CIM)621
暂停
2 期
Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.Patients with Non-Hodking LymphomaRPCEC00000096Center of Molecular Immunology88
招募中
4 期
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis.Anemia secondary to Chronic Kidney DiseaseRPCEC00000123CIMAB-Center of Molecular Immunology (CIM)425
已完成
不适用
Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution.JPRN-UMIN000016052Inouye Eye Hospital30
已完成
不适用
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.glaucoma or ocular hypertensionJPRN-UMIN000035193Inouye Eye Hospital77